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Major histocompatibility complex (MHC) class I
molecules bind antigenic peptides that are translocated
from the cytosol into the endoplasmic reticulum by the
transporter associated with antigen processing. MHC
class I loading independent of this transporter also exists
and involves peptides derived from exogenously ac-
quired antigens. Thus far, a detailed characterization of
the intracellular compartments involved in this pathway
is lacking. In the present study, we have used the model
system in which peptides derived from measles virus
protein F are presented to cytotoxic T cells by B-
lymphoblastoid cells that lack the peptide transporter.
Inhibition of T cell activation by the lysosomotropic drug
ammoniumchloride indicated that endocytic compart-
ments were involved in the class I presentation of this
antigen. Using immunoelectron microscopy, we demon-
strate that class I molecules and virus protein F co-local-
ized in multivesicular endosomes and lysosomes.
Surprisingly, these compartments expressed high levels
of class II molecules, and further characterization iden-
tified them as MHC class II compartments. In addition,
we show that class I molecules co-localized with class II
molecules on purified exosomes, the internal vesicles of
multivesicular endosomes that are secreted upon fusion
of these endosomes with the plasma membrane. Finally,
dendritic cells, crucial for the induction of primary im-
mune responses, also displayed class I in endosomes
and on exosomes.
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Major histocompatibility complex (MHC) class I and class II
molecules have evolved to capture peptides proteolytically
derived from endogenous or exogenous protein sources,
respectively (1–3). Endogenous antigenic peptides are gen-
erated in the cytosol by the proteasome (4), and these
peptides enter the lumen of the endoplasmic reticulum (ER)
by translocation through the transporter associated with anti-
gen processing (TAP) (5–7). MHC class I molecules, consist-
ing of heavy chain (HC):b2-microglobulin (b2m) heterodimers,
require stabilization by antigenic peptides to allow transport
from the ER to the Golgi complex and plasma membrane for
presentation to CD8 T cells. Proteolytic processing of ex-
ogenous proteins, as well as binding of generated peptides
to MHC class II molecules, occur in the endocytic system
(8,9). MHC class II molecules, consisting of two transmem-
brane glycoproteins a and b, are expressed by antigen-pre-
senting cells (APCs), like B cells, macrophages and dendritic
cells (DCs). The majority of intracellular MHC class II
molecules is located in endosomal:lysosomal compartments
(10), which have been termed MIICs, for MHC class II-en-
riched compartments (11,12). Peptide loading can occur in
different types of endocytic compartments, comprising early
endosomes (EEs), late endosomes (LEs) and lysosomes,
depending on cell type and source of antigen (8,13–15).
In the last few years, several studies have shown that exoge-
nous peptides can also be presented in the context of class
I molecules, a phenomenon with major implications for the
peptide repertoire that can be presented to cytotoxic T cells
(16–18). Antigen, taken up via phagocytosis or macropinocy-
tosis by either macrophages or DCs, can enter the classical
pathway for presentation by class I (19–21), either by possi-
ble membrane rupture of the phagosome (17) or by a selec-
tive transport mechanism (22). This presentation pathway
requires the proteasome machinery, TAP, and newly synthe-
sized class I molecules (23,24). On the other hand, there
have been several reports on TAP-independent processing of
antigens for CD8 T cell recognition (25–27), as demon-
strated for peptides derived from exogenously applied inacti-
vated virus particles, virus-like particles and glycopeptides
(16,18). In contrast to TAP-dependent presentation, this path-
way requires only low-antigen doses to elicit a response and
is inhibited by an increase of the endosomal pH, i.e. by the
lysosomotropic drug ammoniumchloride (NH4Cl), and inde-
pendent of newly synthesized class I molecules. These ob-
servations suggest a role for endocytic compartments in
peptide binding to recycling class I molecules.
The purpose of the present study was to explore the pres-
ence and function of class I molecules in the endocytic
system. We used human B-lymphoblastoid cell lines (B-
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LCLs) that were infected with measles virus (MV). Recently,
in this system, TAP-independent presentation of the viral
envelope fusion protein F (MV-F) in the context of class I
MHC has been demonstrated (28). In addition, NH4Cl inhib-
ited presentation of MV-F. Our analysis of the endocytic
compartments in B-LCLs by immunoelectron microscopy
(IEM) indicated that class I molecules co-localized with MV-F
protein throughout the endocytic pathway, most prominently
within multivesicular LEs. We did not find clearly distinct
endosomal subtypes for either class I or II molecules, indicat-
ing that MIICs contain class I molecules. As we have demon-
strated for class II molecules (29), one possible pathway for
class I molecules to reach the cell surface may be by fusion
of multivesicular LEs with the plasma membrane. Here we
show that exosomes containing peptide-loaded class I
molecules were indeed released by B cells. The presence of
functional class I molecules in endosomes and on exosomes
may greatly enhance the peptide-repertoire that can be pre-
sented to cytotoxic T cells, especially since we found that
also blood-derived DCs, the most potent APCs, expressed
class I molecules in endosomes and on exosomes.
Results
TAP-independent presentation of MV protein F by MHC
class I molecules and sensitivity to the lysosomotropic
drug NH4Cl
As a model system to study the subcellular compartments
involved in TAP-independent presentation of exogenously
acquired antigens by class I molecules, we used the presen-
tation of MV-F protein from MV. B-LCLs BM28.7 (parent cell
line to BM36.1), TAP2 mutant BM36.1, and the TAP2 recon-
stituted BM36.1 were all transfected for stable expression of
HLA-B27. Cytolytic T lymphocyte (CTL) clone WH-F40 spe-
cifically recognizes peptides from MV-F in the context of
class I human leukocyte antigen (HLA)-B27 molecules (30).
When pulsed with the specific peptide, all three cell types
were killed with equal efficiency by CTL clone WH-F40, as
shown for different effector: target ratios (Figure 1). Interest-
ingly, a significant percentage of BM36.1 cells were lysed
after infection with MV, despite the fact that they lack TAP2
(Figure 1B). In TAP2 reconstituted BM36.1 cells, the lysis
percentage was similar to the parent cell line (Figure 1C).
These results suggest that, apart from TAP-dependent pre-
sentation, an alternative pathway, independent of TAP, exists
to present MV-F to CTL.
To investigate whether endocytic compartments were in-
volved in the presentation of MV-F, we examined the effect
of the lysosomotropic drug NH4Cl on presentation efficiency
in a proliferative assay. This drug neutralizes endosomal pH,
thereby affecting protein recycling from endosomes and dis-
turbing endosomal antigen processing (31). Because NH4Cl
prevents killing by CTLs, and thus cannot be used in the
killing assay described above, we had to monitor T cell
activation in a proliferation assay. The B-LCLs 8.16, 95.3, and
JP were infected with MV in the presence or absence of
NH4Cl and, after fixation, used to stimulate the T cell clones
WH-F24 and JPIII.8. MV infection of cells occurred at neutral
pH and was not affected by NH4Cl (32, 33, and data not
shown). Table 1 shows that NH4Cl inhibited presentation of
MV-F protein to class I-restricted T cells in different B cell
lines, most dramatically in JP cells with 84% inhibition of T
cell proliferation. We found a similar effect on presentation in
Figure 1: TAP-independent pre-
sentation of the MV-F protein by
HLA-B27 molecules to human CTL.
Parent cell line BM28.7 (A), TAP2
mutant BM36.1 (B), as well as the
TAP2 reconstituted BM36.1 (C), all
transfected for stable expression of
HLA-B27, were infected with MV
(closed circles), mock-infected (trian-
gles), or pulsed with MV-F peptide
(squares) as described. Cells were
subsequently labeled with 51Cr and
used as targets for killing by the MV-
F-specific and HLA-B27-restricted
CTL clone WH-F40 at effector:target
(E:T) ratios of 2:5. On the y-axis, the
percentages of specific lysis (9SD)
are depicted.
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Table 1: Inhibition of MV-F presentation by NH4Cl
Medium MV MVNH4Cl % Inhibition
cpm103 cpm103 cpm103
1.1 14.390.6 9.391.29.5.3 34
1.0 17.490.3 8.193.6 538.1.6
0.1 18.892.7 2.990.3JP 84
Different HLA-B27 B-LCLs were infected with MV in the
absence or presence of NH4Cl. After fixation, cells were used as
APCs in a proliferative assay with T cell clones WH-F24, WH-
F40, or JPIII.8. Numbers represent 3H-thymidine uptake (cpm
103) of representative experiments. The right column shows the
percentage of inhibition of T cell proliferation by NH4Cl.
Characterization of class I-positive endosomes
In a previous IEM study on the human B-LCL JY, we were
unable to detect appreciable amounts of class I molecules in
late endocytic compartments. In the light of the present data,
we further explored the occurrence of class I molecules in
endocytic compartments of the B cell lines JP and RN, and
reinvestigated JY cells. By morphological criteria and marker
distribution, three major types of endocytic compartments
were distinguished: EEs, LEs, and lysosomes (see 12 for
detailed characterization). The most prominent class I-posi-
tive structure in JP (Figure 2B,C, Figure 3B) and RN cells
(Figures 4 and 5) were multivesicular LEs, but in addition
EEs, identified by double-labeling for the EE marker transfer-
rin receptor (TfR) (Figure 4A), and lysosomes (Figure 4C)
contained significant class I labeling (Table 2). Importantly,
the labeling patterns of b2m and HC were similar (Figure 5A,
inset), suggesting that functional class I molecules could be
formed in endosomes. In JY cells, the labeling of class I in
endosomes was very low, of which most was found in EEs
(Table 2). The data confirm our previous findings in these
cells (11). Multivesicular LEs were distinguished from lyso-
somes mainly by morphological criteria, i.e. the presence of
many internal membrane vesicles or membrane sheets (12),
respectively, and the arrival time of endocytic tracers (12,29).
Furthermore, the lysosomal membrane proteins LAMP-1 and
CD63, although present in both compartments, were more
abundant on lysosomal membranes (Figure 4B,C). The rela-
tive distribution of class I molecules over plasma membrane,
biosynthetic organelles, and endosomal compartments indi-
cated that, in the RN cells, 5% of the total gold particles
were present in endosomes and lysosomes, while 3% were
located in ER and Golgi membranes. As expected, the major-
ity (92%) were present at the cell surface. In contrast, count-
ings on BM36.1 showed that 61% of the total class I was
present on membranes of the ER and Golgi complex, due to
insufficient peptide loading and retention of class I in the
biosynthetic pathway in the absence of TAP. Still, we found
that 34% of the labeling was present on the plasma mem-
brane and 3% in endosomes and lysosomes, indicating that
also in TAP mutant cells, class I molecules can reach
endosomes.
Presence of class I molecules in MIICs
Endocytic compartments in human B cells are enriched in
class II molecules, and are termed MIICs (11,12). The obser-
vation that many of the endocytic compartments in B cells
were class I-positive prompted us to examine whether class
I and II molecules localized to the same compartments or if
subtypes existed. As indicated above, in JY cells, only EEs
displayed significant class I labeling and the overlap with
class II labeling was minute. However, in JP (Figure 3B) and
RN cells (Figure 5), class I and II molecules co-localized in all
types of endocytic compartments, including EEs, LEs, and
lysosomes. Class I molecules also co-localized with invariant
chain, a chaperone that mediates transport of newly synthe-
sized class II molecules to the endocytic pathway (Figure
5B), suggesting that class I and II molecules come together
in the same endocytic compartments.
the presence of the lysosomotropic drug chloroquine (data
not shown), and together, these data demonstrate that endo-
somes play an important role in the presentation of MV-F
protein by class I. Control experiments showed that NH4Cl
did not have any effect on the viability of the APCs, nor on
the expression of class I at the cell surface as measured by
flow cytometry analysis (not shown). Similarly, total DNA and
protein synthesis as measured by 3[H]-TdR and L-[4,5-
3H]leucine incorporation, respectively, were not affected
(data not shown).
Co-localization of MV-F and class I in endosomes
To study the endosomal distribution of class I and MV-F, we
used IEM on JP cells, which showed the most dramatic
reduction of MV-F presentation by NH4Cl (Table 1). JP cells,
infected with MV for 24 h, were fixed and ultrathin cryosec-
tions were labeled with antibodies for class I HC and MV-F.
We found that class I and MV-F co-localized at the cell
surface (Figure 2A) and in multivesicular endosomes (Figure
2B,C). Also, class I molecules in the TAP mutant cells
BM36.1 were located in endosomes (data not shown), sug-
gesting that these compartments may indeed play a role in
the generation of MV-F peptides and their loading onto class
I molecules. Since class I was frequently observed in clathrin-
coated pits and vesicles in close proximity to the cell surface
(Figure 3A), the endosomal class I molecules might be inter-
nalized from the plasma membrane. To investigate the origin
of endosomal class I further, JP cells were treated with
cycloheximide for 6 h to block the supply of newly synthe-
sized class I molecules (16,18). Quantitation of class I im-
munogold labeling revealed that the number of gold particles
for class I in the endocytic tract did not change upon cyclo-
heximide treatment. Both in control and cycloheximide-
treated cells, the average number of gold particles per
LE:lysosome was eight, whereas the biosynthetic pathway
in cycloheximide-treated cells was devoid of class I labeling,
and cell surface expression had decreased by 40%. In con-
trast, class II labeling (illustrated for non-treated JP cells in
Figure 3B) in the same cell samples had decreased by 50%
in endosomal:lysosomal compartments. These data suggest
that, unlike class II molecules, the majority of endosomal
class I molecules did not derive from de novo synthesis and
represented recycling molecules.
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Transport of class I from endosomes to the
extracellular milieu via exocytosis of LEs
We have previously described that in B cells, multivesicular
LEs can fuse with the plasma membrane (29). As a conse-
quence, class II molecules present in the limiting membrane
of LEs are incorporated in the plasma membrane, whereas
the internal vesicles of LEs, which also contain functional
class II molecules, are released into the extracellular medium
as so-called exosomes (29,34). To determine whether endo-
somal class I molecules follow a similar exocytic pathway,
we analyzed the class I content of exosomes by IEM and
biochemically. The term exosomes was first described in
reticulocytes, which release 50–80-nm small-membrane
vesicles during their maturation into red blood cells (35). In
reticulocytes secretion of these vesicles, which originate
from multivesicular compartments of the endocytic pathway,
is a way to eliminate internalized plasma membrane proteins,
such as TfR (36,37). Recent studies show that exosomes of
B-LCLs and DCs, as well as the internal vesicles of LEs, are
enriched in tetraspan proteins (CD37, CD53, CD63, CD81,
CD82), class II molecules, and heat-shock protein hsc73, but
are poor in LAMP-1 and HLA-DM, which are primarily located
at the limiting membranes of LEs and lysosomes (34, 38, 39,
unpublished observations, M.J. Kleijmeer and M. Marsh,
MRC Laboratory for Molecular Cell Biology, UCL, London).
Recently, a study by Zitvogel et al. (40) showed that exo-
somes from mouse DCs have strong anti-tumor effects,
probably mediated by class I presentation to cytotoxic T cells.
Figure 2: Subcellular localization of MV-F and class I heavy chain (HC) in JP cells. Ultrathin cryosections of MV-infected JP cells
were double-immunolabeled for class I HC and MV-F with 10- and 15-nm gold particles, as indicated in the figures. A) Class I HC and MV-F
are both present on the plasma membrane (PM). The arrowheads point at virus particles present at the extracellular face of the PM.
B and C) Co-localization of MV-F with class I HC is observed in multivesicular compartments (stars). A and B 10 nm gold particle labels
Class 1 HC, 15 nm gold particle labels MV-F. C 15 nm gold particle labels MV-F, 10 nm gold particle labels Class 1 HC. Bars, 100 nm.
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Figure 3: Class I in clathrin-coated pits and co-localization of class I and II in JP cells. A) Single-immunolabeling of class I HC on
JP cells shows the presence of HC in a clathrin-coated pit and vesicle (arrowheads). PM, plasma membrane. B) Double-immunolabel-
ing of HC (15 nm) and class II (10 nm) shows abundant labeling for both class I and II in multivesicular LE and multilaminar lysosomal
(L) compartments. G, Golgi complex, M, mitochondrion. Bars, 100 nm.
Class I molecules have not been demonstrated on B cell-
derived exosomes before, and interestingly, by IEM, RN cells
showed many class I-carrying exosomes in exocytic profiles
at the plasma membrane (Figure 6A). CD81, one of the
exosomal tetraspan proteins (Figure 6A), localized to the
same exosomal vesicles. To further explore these findings,
exosomes were isolated from culture media of RN cells by
differential centrifugation as described before (29,34). The
exosome-enriched pellet (P5, obtained after a final centrifuga-
tion step at 70000g) was analyzed by whole-mount IEM
and biochemically. Double-immunolabeling with antibody
W6:32, specifically recognizing complexed heterodimeric
class I molecules (41) and with class II antibody showed the
presence of both molecules on typical 50–80-nm exosomes
(Figure 6B). These results indicate that exosomes contain
functional class I molecules. Next, pellets P1 (cells) to P5
(exosomes) were subjected to sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) and Western
blotting to study the presence of class I HC, b2m, and TfR
(Figure 7A,B,C, respectively). The amounts of these proteins
recovered in P1 and P5 were determined and the ratios P5:P1
were calculated. The P5:P1 value for TfR, an established
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marker for plasma membrane and limiting membrane of
EEs, but with a low abundance in internal LE vesicles and
exosomes, was used as a reference to determine the rela-
tive enrichment of class I HC and b2m in exosomes
(15,16). As shown in Table 3, exosomes from RN cells
exhibited a 6-fold enrichment of class I HC and a 2.4-fold
enrichment for b2m over TfR (Figure 7, Table 3). The lower
enrichment factor for b2m indicated that either a proportion
of b2m was lost during the experiment or that also free
HCs were present in exosomes. As a control, P1:P5 values
from the media of JY cells, which also secrete exosomes
(29), were analyzed for the presence of class I HC. As
expected from the low abundance of class I in multivesicu-
lar LEs of JY cells, no enrichment for the HC was found
(Figure 7A).
Class I and II molecules co-localized to endocytic
compartments and exosomes of DCs
An important role for loading of class I molecules with exoge-
nous antigens exists in the event of cross-priming, whereby
professional APCs induce cytotoxic T cells against foreign
antigenic material in vivo (18). Since DCs are the most potent
APCs and are likely to be involved in cross-priming (42), we
next examined the presence of class I molecules in endo-
cytic compartments of these cells. DCs exist in two states:
as immature cells that endocytose very efficiently and pro-
cess antigens and as mature cells specializing in antigen
presentation (42). To obtain DCs, human monocytes were
treated with GM-CSF and IL-4 for 12 days. Maturation of
these cells was induced by incubation in a mixture of tumor
necrosis factor (TNF)a, lipopolysaccharide, and CD40 anti-
Figure 4: Characterization of class I-positive compartments in JY and RN cells. A) Ultrathin cryosection of JY cells was
double-immunogold-labeled for HC (10 nm) and TfR (15 nm), showing abundant TfR labeling in an EE, and few gold particles for HC.
B) Cryosection of RN cell double-immunogold-labeled for HC (10 nm) and LAMP-1 (15 nm). Three lysosomes (L), with internal
membranes and electron-dense material, show labeling for LAMP-1 primarily at the limiting membrane, and HC labeling enriched on
the internal membranes. C) Cryosection of RN cell double-immunogold-labeled for CD63 (15 nm) and HC (10 nm). CD63 is localized
to the limiting and internal membrane sheets of the lysosome, whereas HC labeling is enriched on the internal vesicles of the
lysosome and the LE on the right. Note that the internal vesicles and sheets are separated within the lysosome, suggestive of a recent
fusion event between an LE and lysosome. Bars, 100 nm.
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Figure 5: Co-localization of class I HC with b2m, class II and Ii in endocytic compartments. Ultrathin cryosections of RN cells
were double-immunogold-labeled with antibodies against HC and b-chain of class II (A), HC and b2m (A, inset), HC and invariant chain
(Ii) (B). A) HC (10-nm gold particles) and class II (15-nm gold particles) co-localize in EEs (stars), LEs, and Lysosomes (Ls). The inset
shows a multivesicular LE with HC and b2m labeling. B) EEs, abundantly labeled for Ii (15 nm), are also positive for HC (10 nm). PM
only contains gold particles for HC. Bars, 100nm.
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body for 48 h (43). Immunolabeling showed that class I HC
was present in both EEs and multivesicular LEs, together
with class II molecules (Figure 8A, Table 2). Of the total class
I labeling present in these cells, 9% was located in endo-
somes. In agreement with the presence of class I in LEs,
DCs are able to secrete exosomes (39,40). We show now
that class I and II molecules were located together on DC
exosomes (Figure 8B). Since class I was also present in the
limiting membrane of multivesicular LEs (Figure 8), exocyto-
sis of these compartments represents a pathway of insertion
of endosomal class I molecules into the plasma membrane
of DCs.
Discussion
TAP-independent peptide loading of class I molecules has
been reported to involve endocytic compartments
(16,18,25,28,44–48). We have studied the presentation of
MV-F via class I by B-LCLs to further explore the role and
characteristics of such compartments. Stimulation of MV-F-
specific CTL was shown to be partially independent from
TAP, and required acidic endocytic compartments. IEM
showed that class I molecules were present throughout the
endocytic tract, i.e. in EEs, multivesicular LEs, and lyso-
somes, together with MV-F and class II molecules. Multi-
vesicular LEs, containing both class I and II molecules, were
shown to fuse with the plasma membrane and externalize
the internal vesicles as exosomes. Secreted exosomes con-
tained class I molecules, as shown by IEM and biochemical
analysis. Importantly, also in DCs, the most potent type of
APC, class I and II co-localized in endosomes and on
exosomes.
MV-F protein is synthesized as a type I transmembrane
glycoprotein, and is presented predominantly by class I MHC
molecules to CD8 T cells in a TAP-dependent fashion (30).
Using TAP2 mutant cells, we demonstrate here that presen-
tation can also occur independently of TAP, which is in
agreement with data obtained on presentation of MV-F by
the TAP-deficient cell line T2 (28). The weak base NH4Cl
inhibited class I-restricted MV-F presentation. Furthermore,
class I HC, b2m, and MV-F co-localized in endosomes, sug-
gesting that MV-F could be processed and bound to class I
somewhere in the endocytic tract. What fraction of the
endosomal class I molecules is functional or destined for
degradation (49) remains to be determined. The antibody that
we used against class I HC did not allow us to distinguish
between free or complexed HCs and antibodies recognizing
peptide-loaded class I molecules failed to react in immunola-
beling on ultrathin cryosections. However, a subcellular frac-
tionation study on MelJuSo cells (28) has shown that LEs
and lysosomes contain mature class I molecules by immuno-
precipitation with conformation specific W6:32 antibody,
which recognizes mature heterodimeric class I complexes.
This antibody also showed reactivity in our whole-mount IEM
on exosomes, implying that class I molecules in multivesicu-
lar LEs contain peptide. Another strong indication that class I
molecules on exosomes are functional comes from a study
on DC-derived exosomes, which are capable of stimulating
CD8 T cells in vitro (40).
Endosomal class I molecules are probably not derived from
the biosynthetic pathway (50,51), but represent recycling
surface molecules (52–56), since a blockade in protein syn-
thesis for 6 h with cycloheximide did not lower the level of
class I in endocytic compartments. In addition, class I was
present in clathrin-coated pits of the plasma membrane. This
is in agreement with observations that an endosomal path-
way of class I-restricted presentation is not affected by
cycloheximide, nor by brefeldin A, an agent interfering with
transport of newly synthesized proteins from the ER
(16,44,47,57). MHC class I loading with MV-F-derived pep-
tides in endosomes most likely involves peptide exchange of
pre-loaded class I. Indeed, that class I molecules are able to
exchange peptides at acidic pH is indicated by the fact that at
pH 5, which corresponds with the pH of LEs and early
lysosomal compartments, peptide-receptive ‘empty’ class I
molecules can be generated (28).
LEs and lysosomes play a major role in class II antigen
presentation, a reason why these compartments in APCs
have been collectively termed MIICs (11). MIICs were first
described in the B cell line JY, which harbors almost no
endosomal class I molecules, suggesting an exclusive role of
these compartments in class II presentation (11). However,
our present observations show that JY cells are exceptional
among 10 different B cell lines with respect to the low
abundance of class I in endosomes (present study, C.
Rabouille, unpublished observations). Changes in rates of
endocytosis and degradation of class I molecules might be
influenced by the cell’s state of differentiation, which may
explain differences in the amount of endosomal class I
molecules (52). Since DCs also contain class I molecules in
endosomes (40, present study), it is more likely that endo-
Table 2: Distribution of MHC class I heavy chain (HC) in endo-
cytic compartments
Gold %Gold%Gold%
JP 60 791 483 5894 296 3594
RN 41 1791 137 5693 66 2794
8249411599128JY 1694
DC 69 3390 108 5294 20 1695
Endocytic compartments were subdivided in three major types:
early endosomes (EE), multivesicular late endosomes (LE) and
lysosomes (L). The columns on the left below each compart-
ment show the total number of gold particles counted in 20 cell
profiles on this compartment. The respective percentages9
SEM, based on three countings of 20 cell profiles, are displayed
in the right hand columns.
131Traffic 2001: 2: 124–137
Kleijmeer et al.
Figure 6: Class I immunolabeling of exosomes. PM of RN cell, with exosomes (E) associated at the external face in a fusion profile.
The exosomes are labeled for HC (10 nm) and the tetraspan protein CD81 (15 nm). B) Whole-mount EM of isolated RN exosomes,
immunolabeled with class II antibody (15 nm) and W6:32, specific for antigen-loaded class I (10 nm). Bars, 200 nm.
cytic compartments in APCs are not solely involved in class II
functioning, but in addition, may serve in the processing and
loading of exogenous antigen onto class I.
A physiological role for class I molecules in endosomes may
be the event of cross-priming, whereby cytotoxic T
lymphocytes are primed for antigens derived from cells in the
132 Traffic 2001: 2: 124–137
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Figure 7: Detection of class I molecules on exosomes by Western blotting. Exosomes were isolated from RN and JY culture
media by differential centrifugation, resulting in the pellets P1 (cells), P2–4, P5 (exosomes). The pellets were analyzed by SDS-PAGE
and Western blotting. HC and b2m are both present in P5 of RN cells (A, B), whereas TfR is absent (C). JY cells show no enrichment
of HC in P5 (A).
periphery (58,59). It has been shown that this presentation
pathway requires professional APCs and CD4 T helper
cells, which indirectly prime cytotoxic T cells (60,61). Re-
cently, it was found that the help provided by these T cells
could be replaced by signaling through CD40 (62,63), which
implicates that APCs may directly cross-present cellular
antigens to CD8 T cells. These cellular antigens, which
can be derived from apoptotic bodies (64), can enter the
APC via different mechanisms of endocytosis (18,65), and
the association of antigenic peptides with class I molecules
can occur either via the TAP-dependent pathway, or in en-
docytic compartments. Since we and others find class I
molecules in endosomes of DCs (present study, 40), the
latter mechanism could indeed be valid in the most potent
APC of all.
The presence of class I molecules on exosomes indicates
that peptide-loaded class I may reach the cell surface via
fusion of multivesicular LEs with the plasma membrane.
Exosomes can be isolated from the culture medium by dif-
ferential centrifugation (29). The selective enrichment of
proteins, like tetraspanins, hsc 73, co-stimulatory and MHC
molecules in exosomes (29,34,39) suggests that they serve
a role in the immune response. It has been shown that B
cell-derived exosomes can activate CD4 T cells in vitro,
and interestingly exosomes from DCs are able to eradicate
established tumors in mice (40). The mechanism underlying
this process is largely unknown, but does require the pres-
ence of class I on exosomes. From our biochemical and
IEM data, it is clear that exosomes derived from B cells
and DCs (40) express abundant mature class I molecules,
implying that they have peptide-binding capacity, and could
play a role in the class I-restricted immune response.
Table 3: Relative enrichment of class I HC and b2m over TfR in
exosomes
Enrichment over TfR (fold)P5:P1
0.5990.16 (6)Class I HC 6.0991.62
Class I b2m 0.2390.13 (6) 2.4191.41
0.1090.01 (3) 1TfR
The signals from P5 and P1, obtained as in Figure 7, were
quantified with a PhosphoImager and the average ratios (P5:
P19SD) obtained from independent experiments are presented
in the first column (number of determinations in parentheses).
The relative enrichment of HC and b2m was determined by
normalizing their ratio P5:P1 value to that of TfR.
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Figure 8: Class I and II in endosomes and on exosomes of human blood-derived DCs. DCs were isolated from blood as described
and ultrathin cryosections were immunolabeled for class I HC and class II molecules. A) Class I HC (HC; 10 nm) co-localizes with class
II molecules (15 nm) in an EE and multivesicular LE and on exosomes (arrowheads) located at the extracellular site of the PM in B.
Bars, 200 nm.
Materials and Methods
Cells
The Epstein–Barr virus-transformed B-LCLs 8.16, 9.53, JP, as well as
the TAP2 mutant cell line BM36.1 and its parent cell line 28.7, were
used as APCs (30,66,67). RN and JY were maintained as described
previously (29). The construction and characterization of HLA-B27
transfectants of BM36.1 and 28.7 have been described previously
(30). Reconstitution of HLA-B27 BM36.1 with a functional TAP2
molecule was established by transfection of TAP2 cDNA (gift of Dr J.
Trowsdale, Cambridge, UK) ligated in the episomal expression vector
pREP8, containing the histodinol resistance gene (InVitroGen).
DCs were generated from human peripheral blood mononuclear cells
(PBMC) as described by Romani et al. (43). Briefly, PBMC were
prepared from buffy coats of healthy donors by Ficoll–Paque density
gradient centrifugation (Pharmacia and Upjohn, Uppsala, Sweden). T
cells were removed by two rounds of rosetting at 4°C with sheep
erythrocytes. The remaining cells were resuspended at 3–4106
cells:ml in Roswell Park Memorial Institute (RPMI)-1640 medium
(Gibco, Scotland) supplemented with 8% heat-inactivated fetal calf
serum (FCS) (Hyclone Laboratories, Logan, UT) and distributed in
6-well tissue-culture plates (Costar, Badhoevedorp, the Netherlands)
at 3 ml:well. After 2 h incubation at 37°C, the plates were gently
whirled and non-adherent cells were washed away. The remaining
and loosely adherent cells were cultured in 3 ml of RPMI containing
8% FCS, 500–1000 U:ml recombinant human interleukin-4 (Intergen,
New York, NY) and 800 U:ml recombinant human GM-CSF. Half of
this culture medium was replenished every second day. After 12
days in culture, DCs were harvested and incubated with a mixture of
50 ng:ml lipopolysaccharide (Braunsweig), 30 ng:ml TNFa (Genzyme,
Cambridge, MA) and 25 mg:ml anti-CD40 (clone S2C6, Mabtech AB,
Sweden) for 48 h and finally fixed for IEM.
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Antibodies
The following monoclonal antibodies were used: anti-b2m BBM-1
(kind gift of Dr J.J. Neefjes, NKI, Amsterdam, the Netherlands),
H68.4 against TfR (Zymed Lab., San Francisco, CA), CLB gran 1:2,
435 against CD63 (CLB, Amsterdam, the Netherlands), H4A3 against
LAMP-1 (CD107a; Pharmingen, San Diego, CA), and W6:32 (DAKO,
Glostup, Denmark) against MHC class I heterodimeric complexes.
The rabbit polyclonal antibodies were: anti-TfR (kind gift of Dr A.
Schwartz), 631 69 to b2m, anti-MHC class I HC (both kind gifts of Dr
J.J. Neefjes, NKI), anti-MHC class II (kind gift of Dr H.L. Ploegh,
Department of Pathology, Harvard Medical School, Boston, MA),
anti-luminal epitope of invariant chain antibody ICC5 (68; kind gift of
Dr P.A. Morton, Monsanto, St Louis, MO), K9 against MV-F (obtained
from RIVM, Bilthoven, the Netherlands), and anti-IgG from DAKO.
Presentation assays
MV-infected or peptide-pulsed APCs were used as target cells in a
51Cr-release assay or, after fixation, as stimulator cells in a prolifera-
tive T cell assay as described (30). The CD8 CTL clones WH-F24
and WH-F40 were HLA-B*2705-restricted and MV-F protein (aa se-
quence RRYPDAVYL)-specific (30). JP III.8 was a CD8, class I-re-
stricted MV-F protein-specific T cell clone obtained from a patient
with acute measles (30). To investigate the effects of lysosomotropic
drugs on MHC class I-restricted presentation of the MV-F protein, the
HLA-B27 APCs 8.16, 9.53 and the autologous JP B-LCLs were
infected with MV in the presence or absence of NH4Cl (20 mM in
RPMI-1640, 1% FBS) for 1 h, washed twice, and further cultured in
RPMI, 10% FBS, and the indicated concentration of NH4Cl, where
after the cells were fixed with paraformaldehyde (30).
IEM
Cells were fixed and prepared for ultrathin cryosectioning and im-
munolabeling as described previously (69). Briefly, cells were fixed in
2% paraformaldehyde or in a mixture of 2% paraformaldehyde:0.2%
glutaraldehyde in phosphate buffer. After washing with phosphate
PBS and PBS:50 mM glycine, cell pellets were embedded in 10%
gelatin, cut in small blocks, and infiltrated with 2.3 M sucrose at 4°C
for 4 h. Finally, the blocks were mounted and frozen in liquid nitro-
gen. Ultrathin cryosections were indirectly immunolabeled with 10-
nm protein A gold particles in single-immunolabeling experiments
and with 10 and 15 nm in double-immunolabeling experiments.
Sections were embedded in a mixture of 2% methyl cellulose and
0.4% uranyl. When indicated, JP cells were incubated with 100 mg:ml
cycloheximide for 6 h and then fixed and processed for IEM as
described.
Semi-quantitative analysis of HC distribution
Ultrathin cryosections of JY and RN cells, and mature cytokine-
derived DCs were single-immunolabeled with HC antibody and 10-
nm protein A gold particles. In 320 cell profiles of each cell type,
gold particles present on endocytic compartments were counted
when within a 20-nm range of a membrane and designated to EEs,
multivesicular LEs, or lysosomes, as detailed in Table 2. To determine
the relative distribution of class I molecules, gold particles were
counted on membranes of ER, Golgi complex, plasma membrane,
and endosomes. Ultrathin cryosections of control and cycloheximide-
treated JP cells were immunolabeled with HC antibody and, in each
quantitation, 50 endosomes:lysosomes were randomly selected.
Plasma membrane length was measured by a point-hit method.
Isolation of exosomes
Exosomes were isolated by differential centrifugation as previously
described (29,34). Briefly, RN cells were washed by centrifugation
and re-cultured in fresh medium for 18 h. Cell culture media (35 ml)
containing about 5107 cells were centrifuged once for 10 min at
200g (pellet P1), twice for 10 min at 500g (pellet P2), twice for
15 min at 2000g (pellet P3), once for 30 min at 10000g (pellet P4),
and finally once for 60 min at 70000g (pellet P5) using a rotor SW27
(Beckman Instruments, Fullerton, CA). P1 corresponds to cells and P5
to the fraction enriched in exosomes. P1-P5 were directly solubilized
in reducing or non-reducing SDS sample buffer, incubated for 5 min
at 95°C, and submitted to SDS-PAGE and Western blotting. For
whole-mount EM, membranes from P5 were floated into a sucrose
gradient, adhered to a grid, fixed in 2% paraformaldehyde and dou-
ble-immunolabeled for class I and II molecules.
Immunoblotting
After SDS-PAGE, the proteins were transferred to Immobilon-P mem-
brane (Millipore, Bedford, MA). The membranes were then blocked
for 90 min in PBS containing 5% (w:v) non-fatty dry milk Protivar
(Nutricia, Zoetermeer, the Netherlands) with 0.1% (w:v) Tween 20
(blocking buffer) and reacted for 90 min with the primary antibody,
followed by detection with 0.1 mg:ml of 125I-labeled recombinant
protein-G (Zymed Lab.) for 90 min. For detection of monoclonal
antibodies, a rabbit anti-IgG was used as an intermediate. 125I was
detected and analyzed using a PhosphoImager (Molecular Dynamics,
Sunnyvale, CA).
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